Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

Screening of HIV-infected patients for non-AIDS-related morbidity: an evidence-based model of practice

Rosalind Foster A C , Sian Morris A , Nathan Ryder A B , Lynne Wray A B and Anna McNulty A B
+ Author Affiliations
- Author Affiliations

A Sydney Sexual Health Centre, GPO Box 1614, Sydney, NSW 2001, Australia.

B School of Public Health and Community Medicine, University of NSW, Randwick, NSW 2052, Australia.

C Corresponding author. Email: rosalind.foster@talk21.com

Sexual Health 8(1) 30-42 https://doi.org/10.1071/SH10021
Submitted: 18 February 2010  Accepted: 30 July 2010   Published: 24 January 2011

Abstract

Objective: To develop guidelines to facilitate management of HIV infection as a chronic disease within the setting of a sexual health or other HIV outpatient clinic. Methods: We undertook a literature search to identify published guidelines and expert panel commentaries on screening and managing non-AIDS comorbidities in the general and HIV-infected population. We developed evidence-based guidelines for screening and management of non-AIDS comorbidities in HIV-positive clients attending the Sydney Sexual Health Centre (SSHC) that could be used in other HIV outpatient settings. Results: Guidelines have been developed that describe the recommended tests and an interpretation of results, and outline actions to take if abnormal. A summary document can be placed in the medical notes to record completed tests, and resources such as lifestyle modification pamphlets and cardiovascular risk assessment tools made easily available in clinics. Conclusions: These guidelines are being used by nurses and doctors to facilitate the management of HIV as a chronic disease in the SSHC. This represents a significant shift in practice from the traditional role of a sexual health clinic, and is likely to become increasingly important in resource-rich countries such as Australia where individuals with HIV are expected to live beyond their seventh decade. This model could be used in other HIV outpatient settings including general practice.

Graphical Abstract Image

Additional keywords: cardiovascular disease, chronic disease, renal disease.


References


[1] The Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372 293–9.
CrossRef | PubMed |

[2] Lewden C,  May T,  Rosenthal E,  Burty C,  Bonnet F,  Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the Mortalite 2000 and 2005 surveys. J Acquir Immune Defic Syndr 2008; 48 590–8.
CrossRef | PubMed |

[3] Sackoff JE,  Hanna DB,  Pfeiffer MR,  Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145 397–406.
PubMed |

[4] Deeks SG,  Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338 a3172.
CrossRef | PubMed |

[5] Lohse N,  Eg Hansen AB,  Pedersen G,  Kronberg G,  Gerstoft J,  Toft Sorensen H, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146 87–95.
PubMed |

[6] Phillips AN,  Neaton J,  Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22 2409–18.
CrossRef | PubMed |

[7] Kuller LH,  Tracy R,  Belloso W,  De Wit S,  Drummond F,  Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5 e203.
CrossRef | PubMed |

[8] Baker JV,  Peng G,  Rapkin J,  Abrams DI,  Silverberg MJ,  MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22 841–8.
CrossRef | PubMed |

[9] Ferry T,  Raffi F,  Collin-Filleul F,  Dupon M,  Dellamonica P,  Waldner A, et al. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr 2009; 51 407–15.
CrossRef | PubMed |

[10] Lewden C,  Chene G,  Morlat P,  Raffi F,  Dupon M,  Dellamonica P, et al. HIV-infected adults with a CD4 count greater than 500 cells.mm3 on long-term antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46 72–7.
CrossRef | PubMed |

[11] El-Sadr W, Neaton J for the SMART Study Investigators. Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5–8; Denver, USA. Oral Abstract 106LB.

[12] The Strategies for Management of Antiretroviral Therapy (SMART) study group Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4 cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197 1145–55.
CrossRef | PubMed |

[13] Calza L,  Manfredi R,  Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53 10–4.
CrossRef | PubMed |

[14] Sabin C , Worm S , Weber R , El-Sadr W , Reiss P , Thiebaut R et al, and the DAD study group. Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D Study. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3–6; Boston USA. Abstract 957c.

[15] Gallant JE,  Parish MA,  Kreuly JC,  Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40 1194–8.
CrossRef | PubMed |

[16] Friis-Møller N,  Reiss P,  Sabin CA,  Weber R,  d’Arminio Monforte A,  El-Sadr W, et al. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356 1723–35.
CrossRef | PubMed |

[17] Brown TT,  McComsey GA,  King MS,  Qaqish RB,  Bernstein BM,  daSilva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51 554–61.
CrossRef | PubMed |

[18] Nahvi S,  Cooperman NA. Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev 2009; 21 14–27.
CrossRef | PubMed |

[19] Denholm JT,  Yong MK,  Elliott JH. Long term management of people with HIV. Aust Fam Physician 2009; 38 574–7.
PubMed |

[20] Australasian Society for HIV Medicine. General practitioners and HIV. Sydney: ASHM; 2009. Available online at: http://www.ashm.org.au/images/resources/1976963325_large.jpg [verified 6 February 2010].

[21] Aberg JA,  Kaplan JE,  Libman H,  Emmanuel P,  Anderson JR,  Stone VE, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49 651–81.
CrossRef | PubMed |

[22] European AIDS Clinical Society. Prevention and management of non-infectious co-morbidities in HIV. Paris: European AIDS Clinical Society; 2009. Available online at: www.europeanaidsclinicalsociety.org/guidelines.asp [verified April 2010].

[23] The Royal Australian College of General Practitioners ‘Red Book’ Taskforce. Harris M, Bennett J, Del Mar C, Fasher M, Foreman L, Furler J, et al. in conjunction with The Royal Australian College of General Practitioners Publications Unit. Guidelines for preventive activities in general practice (7th edition). Melbourne: RACGP; 2009. Available online at: http://www.racgp.org.au/guidelines/redbook[verified 6 February 2010].

[24] National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated August 2009. Canberra: National Heart Foundation of Australia; 2009. Available online at: www.heartfoundation.org.au/Professional_Information/Clinical_Practice/Hypertension [verified 5 February 2010].

[25] Kidney Health Australia. Chronic kidney disease (CKD) management in general practice brochure. Melbourne: Kidney Health Australia; 2007. Available online at: http://www.racgp.org.au/guidelines/ckd [verified 5 February 2010].

[26] WHO. Fracture risk assessment tool. Sheffield: World Health Organization Collaborating Centre for Metabolic Bone Diseases. Available online at: http://www.shef.ac.uk/FRAX [verified 5 February 2010].

[27] National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. Canberra: NVDPA; 2009. Available online at: http://www.heartfoundation.org.au/Professional_Information/Clinical_Practice/Pages/default.aspx[verified 5 February 2010].

[28] Diabetes Australia in conjunction with the Royal Australian College of General Practitioners. Diabetes management in general practice: guidelines for type 2 diabetes. Fifteenth edition 2009/10. Melbourne: RACGP; 2009. Available online at: http://www.racgp.org.au/guidelines/diabetes [verified 5 February 2010].

[29] National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Lipid management guidelines 2001 – summary paper. Med J Aust 2001; 175 S57–88.
PubMed |

[30] The Royal Australian College of General Practitioners National Standing Committee – Quality Care in conjunction with the Publications Unit of the RACGP. Smoking, nutrition, alcohol and physical activity (SNAP): a population health guide to behavioural risk factors in general practice. Melbourne: RACGP; 2004. Available online at: www.racgp.org.au/guidelines/snap [verified 5 February 2010].

[31] National Health and Research Medical Council (NHRMC). Overweight and obesity in adults. A guide for general practitioners. Canberra: NHRMC; 2003. Available online at: http://www.health.gov.au/internet/main/publishing.nsf/Content/CF511C5633F62237CA256F190003BC2F/$File/adults_gp.pdf [verified August 2010].

[32] Australian Antiretroviral Guidelines Panel and the Australasian Society for HIV Medicine. The Australian commentary to the USA guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Sydney: ASHM; 2009. Available online at: http://ashm.org.au/projects/arvguidelines/Default.asp?PublicationID=4&ParentSectionID=P4&SectionIS=358 [verified 26 April 2010].

[33] EACS Guidelines. Clinical management and treatment of HIV infected adults in Europe. Version 5. Paris: European AIDS Clinical Society; November 2009. Available online at: http://www.europeanaidsclinicalsociety.org/guidelines.asp [verified 25 April 2010].

[34] Gazzard BG. On behalf of the BHIVA Treatment Guidelines Writing Group. Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9 563–608.
CrossRef | PubMed |

[35] Winston J,  Deray G,  Hawkins T,  Szczech L,  Wyatt C,  Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008; 47 1449–57.
CrossRef | PubMed |

[36] Longenecker CT,  Scherzer R,  Bacchetti P,  Lewis CE,  Grunfld C,  Schlipak MG. HIV viremia and changes in kidney function. AIDS 2009; 23 1089–96.
CrossRef | PubMed |

[37] Choi A , Shlipak M , Hunt P , Martin J , Deeks S . HIV-infected persons continue to lose kidney function despite successful ART. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8–11; Montreal. Canada. Oral abstract 38.

[38] Merck & Co. Crixivan (Indinavir sulphate) package insert. Whitehouse Station: Merck & Co.; 1999.

[39] Kopp JB,  Falloon J,  Filie A,  Abati A,  King C,  Hortin GL, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytological findings. Clin Infect Dis 2002; 34 1122–8.
CrossRef | PubMed |

[40] Day SL,  Leake Date HA,  Bannister A,  Hankins M,  Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J Acquir Immune Defic Syndr 2005; 38 301–4.
PubMed |

[41] Chander G,  Lau B,  Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006; 43 411–7.
CrossRef | PubMed |

[42] Thio CL,  Seaberg EC,  Skolasky R,  Phair J,  Visscher B,  Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360 1921–6.
CrossRef | PubMed |

[43] Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44 S132–9.
CrossRef | PubMed |

[44] British HIV Association guidelines for the management of co-infection with HIV-1 and hepatitis B or C 2010. HIV Med 2010; 11 1–30.


[45] Gastroenterological Society of Australia. Australia and New Zealand chronic hepatitis B (CHB) recommendations. 1st edition. Melbourne: GESA; 2008. Available online at: http://www.gesa.org.au/professional/guidelines/ChronicHepatitisB.cfm [verified 5 February 2010].

[46] Arnsten JH,  Freeman R,  Howard AA,  Floris-Moore M,  Lo Y,  Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21 617–23.
CrossRef | PubMed |

[47] Brown TT,  Qaqish RB. Antiretroviral therapy and the prevalence of osteopaenia and osteoporosis: a meta-analytical review. AIDS 2006; 20 2165–74.
CrossRef | PubMed |

[48] Mallon P . Bone disease and HIV: together for the long term. 9th International Congress on Drug Therapy in HIV infection; 2008 November 09–13; Glasgow, UK. Abstract O322.

[49] Royal Australian College of General Practitioners. Clinical guidelines for the prevention and treatment of osteoporosis in postmenopausal women and older men. Melbourne: RACGP; 2010. Available online at: http://www.racgp.org.au/guidelines/musculoskeletaldiseases/osteoporosis [verified 26 April 2010].

[50] National Osteoporosis Guideline Group. NOGG pocket guide for healthcare professionals: guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Sheffield: NOGG. Available online at: http://www.shef.ac.uk/NOGG/downloads.html [verified 5 February 2010].

[51] Wilson D , Prestage G , Donovan B , Gray R , Hoare A , McCann PD et al Phase A of the National Gay Men’s Syphilis Action Plan: modelling evidence and research on acceptability of interventions for controlling syphilis in Australia 2009. Sydney: National Centre in HIV Epidemiology and Clinical Research; 2009. Available online at: http://www.nchecr.unsw.edu.au/NCHECRweb.nsf/page/SEPPH[verified 5 February 2010].

[52] Fakoya A,  Lamba H,  Mackie N,  Nandwani R,  Brown A,  Bernard EJ, et al. British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. HIV Med 2008; 9 681–720.
CrossRef | PubMed |

[53] NSW Department of Health. Sexually Transmissible Infections Strategy 2006–09. Sydney: NSW Department of Health; 2006. Available online at: http://www.health.nsw.gov.au/policies/pd/2006/PD2006_071.html [verified 5 February 2010].

[54] National Gay Men’s Syphilis Action Plan. Canberra: Blood Borne Virus and STIs Subcommittee (BBVSS) of the Australian Population Health Development Principal Committee; 2009. Available online at: www.stipu.nsw.gov.au [accessed 5 February 2010].

[55] Bourne C,  Edwards B,  Shaw M,  Gowers A,  Rodgers C,  Ferson M. Sexually transmitted infection testing guidelines for men who have sex with men. Sex Health 2008; 5 189–91.
CrossRef | PubMed |

[56] Triant VA,  Lee H,  Hadigan C,  Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus. J Clin Endocrinol Metab 2007; 92 2506–12.
CrossRef | PubMed |

[57] Grunfeld C , Delaney J , Wanke C , Currier J , Scherzer R , Biggs M et al HIV infection is an independent risk factor for atherosclerosis similar in magnitude to traditional cardiovascular disease risk factors. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8–11; Montreal. Canada; Abstract 146.

[58] Friis-Moller N,  Weber R,  Reiss P,  Thiebaut R,  Kirk O,  d’Arminion Monforte A, et al. DAD Study Group. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17 1179–93.
CrossRef | PubMed |

[59] Sabin CA,  Worm SW. Conventional cardiovascular risk factors in HIV infection: how conventional are they? Curr Opin HIV AIDS 2008; 3 214–9.
CrossRef | PubMed |

[60] Wolf K,  Tsakiris DA,  Weber R,  Erb P,  Battegay M,  Swiss HIV Cohort Study Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185 456–62.
CrossRef |

[61] Torriani FJ,  Komarow L,  Parker RA,  Cotter BR,  Currier JS,  Dube MP, et al. for the ACTG 5152s Study Team. Endothelial function in human immunodeficiency virus-infected antiretroviral-naïve subjects before and after starting potent antiretroviral therapy: the ACTG study 5152s. J Am Coll Cardiol 2008; 52 569–76.
CrossRef |

[62] Mangili A,  Jacobson DL,  Gerrior J,  Polak JF,  Gorbach SL,  Wanke CA. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 2007; 44 1368–74.
CrossRef |

[63] Clotet B,  Negredo E. HIV protease inhibitors and dyslipidemia. AIDS Rev 2003; 5 19–24.


[64] Schambelan M,  Wilson PWF,  Yarasheski KE,  Cade T,  Davila-Roman VG,  D’Agostino RB, et al. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008; 118 e48–53.
CrossRef |

[65] Australian guidelines to reduce health risks from drinking alcohol. Canberra: Australian Government National Health and Medical Research Council; 2009. Available online at: http://www.nhmrc.gov.au/publications/synopses/ds10syn.htm [accessed 5 February 2010].



Rent Article (via Deepdyve) Export Citation